Abstract: A composition, suitable for an orally administered formulation, contains a GLP-1 analogue and, particularly, a hydrophobic ion-pair of a GLP-1 analogue and an oil phase. The pharmaceutical composition for oral administration forms an emulsion surrounding the hydrophobic ion-pair when exposed to a water phase, so as to be stably absorbed without being decomposed by digestive enzymes, and thus provides an effective and prolonged pharmacological effect. Methods for producing the composition for oral administration are also disclosed.

Abstract: A shift-by-wire transmission system includes a gear shifting operation portion provided at an end portion of a body and configured to shift a gear, a housing provided inside the body, a haptic element provided in contact with the housing and configured to generate a vibration when the gear is shifted to a predetermined gear shifting stage to transmit the vibration to the housing, and a groove member coupled to the gear shifting operation portion and configured to operate in conjunction with a gear shifting operation of the gear shifting operation portion and transmit the vibration of the haptic element, which is transmitted to the housing, to the gear shifting operation portion by constantly maintaining a state in contact with the housing.

Abstract: A shift-by-wire transmission system includes a body provided with a sensor therein; an operation portion assembly in which a magnet is provided within a detecting range of the sensor, wherein a gear shifting operation portion is rotated about an axis of the body so that the magnet is rotated with the gear shifting operation portion, and the gear shifting operation portion is moved in an axial direction of the body so that the magnet is linearly moved together with the gear shifting operation portion; and a controller configured to detect a variation in magnetic force of the magnet detected by the sensor according to a rotational displacement and a movement displacement of the magnet and detect a gear shifting signal corresponding to a gear shifting operation of the gear shifting operation portion.

Abstract: One aspect provides a pharmaceutical composition and a pharmaceutical combination formulation contains the same, the pharmaceutical composition containing as active ingredients: a proton pump inhibitor or a pharmaceutically acceptable salt thereof; and an antacid selected from magnesium hydroxide, magnesium oxide, or a mixture thereof.

Abstract: Provided are a pharmaceutical composite formulation and a method of preparing the same, the pharmaceutical composite formulation including: a first layer containing, as an active ingredient, a proton pump inhibitor or a pharmaceutically acceptable salt thereof and a lubricant, and a second layer containing, as an active ingredient, an antacid selected from magnesium hydroxide, magnesium oxide, and a mixture thereof.

Abstract: An aspect provides a pharmaceutical composite formulation containing: a first layer comprising a proton pump inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient, a disintegrant, and a binder; and a second layer comprising, as an active ingredient, an antacid selected from magnesium hydroxide, magnesium oxide, or a mixture thereof.

Abstract: The present disclosure relates to a pharmaceutical composition containing esomeprazole or a pharmaceutically acceptable salt thereof and with a dual release profile, and particularly to a pharmaceutical composition which exhibits a dual release profile of immediate release and sustained release so that long-term efficacy can be sustained. The pharmaceutical composition containing esomeprazole or a pharmaceutically acceptable salt thereof and with a dual release profile, according to the present disclosure, can secure bioavailability equivalent to that of existing esomeprazole immediate-release/enteric-release formulations, and can maintain long-term efficacy due to the dual release profile thereof even when administered once a day, thus preventing the occurrence of nocturnal acid breakthrough, and accordingly, can be effectively used as a therapeutic agent for nocturnal acid breakthrough.

Abstract: Provided are a pharmaceutical composition including a core in a form of a multi-unit spheroidal tablet (MUST) containing esomeprazole or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition is dissolved by 50 percent (%) or more within 15 minutes of an in vitro dissolution test; and a method of preparing the pharmaceutical composition. According to this, in case that the pharmaceutical composition is developed as the multi-unit spheroidal tablet, the dissolution may be accelerated in a condition of a slow stirring rate than that of a conventional pellet formulation or single tablet. Also, proton pump inhibitors (PPI)-based drugs including esomeprazole may be dissociated by gastric acid having a low pH, consequently inducing a decrease in bioavailability of the drug, but the pharmaceutical composition according to this may be minimize this.

Abstract: Disclosed is a pharmaceutical combination formulation comprising a first discrete part containing amlodipine and rosuvastatin and a second discrete part containing losartan, which exhibits improved dissolution rate and stability. The inventive combination formulation comprising amlodipine, losartan and rosuvastatin having different action mechanisms from one another can be effectively used to prevent or treat a cardiovascular disorder. Designed to minimize an interaction among active ingredients, the pharmaceutical combination formulation exhibits excellent storage stability and dissolution rates of amlodipine, losartan and rosuvastatin, and thus can be useful in pharmaceutical industries.

Abstract: Disclosed is a pharmaceutical combination formulation comprising a first discrete part containing amlodipine and rosuvastatin and a second discrete part containing losartan, which exhibits improved dissolution rate and stability. The inventive combination formulation comprising amlodipine, losartan and rosuvastatin having different action mechanisms from one another can be effectively used to prevent or treat a cardiovascular disorder. Designed to minimize an interaction among active ingredients, the pharmaceutical combination formulation exhibits excellent storage stability and dissolution rates of amlodipine, losartan and rosuvastatin, and thus can be useful in pharmaceutical industries.